




COMPLETE

NUTIDE:701 - PART 2

SOLID TUMOR - PHASE 2 STUDY (MONOTHERAPY)

Designed to confirm the dose of NUC-7738



Number of patients

11

Age (median)

64

(range 42-74)

Prior lines of therapy (median)*

1

(range 1-5)

* for advanced disease


NUC-7738 is well tolerated in patients who have exhausted all other therapies

	NUC-7738 (n=11)		
	All Grades, n(%)	Grade 3, n(%)	Grade 4, n(%)
Nausea	5 (46%)	0	0
Anemia	5 (46%)	1 (9%)	0
Vomiting	4 (36%)	0	0
Fatigue	4 (36%)	1 (9%)	0
Diarrhea	3 (27%)	0	0
Constipation	2 (18%)	0	0
Blood creatinine increase	2 (18%)	0	0
Flushing	2 (18%)	0	0
Infusion related reaction	2 (18%)	0	0

- No Grade 4 toxicities
- RP2D refined to 1125 mg/m²

Most frequent (≥10% population) NUC-7738 related AEs

Prolonged disease control in patients who have exhausted all treatment options



Key takeaways

NUC-7738 has shown prolonged disease control in patients who have exhausted all other treatment options

NUC-7738 has a favorable safety profile

RP2D is 1125 mg/m²